98%
921
2 minutes
20
Auranofin (AF), a former rheumatoid polyarthritis treatment, gained renewed interest for its use as an antimicrobial. AF is an inhibitor of thioredoxin reductase (TrxB), a thiol and protein repair enzyme, with an antibacterial activity against several bacteria including C. difficile, an enteropathogen causing post-antibiotic diarrhea. Several studies demonstrated the effect of AF on C. difficile physiology, but the crucial questions of resistance mechanisms and impact on microbiota remain unaddressed. We explored potential resistance mechanisms by studying the impact of TrxB multiplicity and by generating and characterizing adaptive mutations. We showed that if mutants inactivated for trxB genes have a lower MIC of AF, the number of TrxBs naturally present in clinical strains does not impact the MIC. All stable mutations isolated after AF long-term exposure were in the anti-sigma factor of σ and strongly affect physiology. Finally, we showed that AF has less impact on human gut microbiota than vancomycin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405772 | PMC |
http://dx.doi.org/10.1038/s41522-024-00551-3 | DOI Listing |
Pulm Ther
September 2025
Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.
Introduction: The modification of an inhaler's air flow resistance influences a patient's inhalation flow profile, thereby affecting the exit velocity of an aerosol leaving the Respimat® mouthpiece. A slower inhalation maneuver results in reduced plume velocity and thus a decreased oropharyngeal deposition due to reduced impaction. This could not only lead to fewer unwanted side effects associated with inhaled therapies, but also enhance lung deposition.
View Article and Find Full Text PDFBreast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.
J Assist Reprod Genet
September 2025
Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Purpose: To determine if melatonin-enriched culture media could offset loss of imprinting in mouse concepti.
Methods: Zygotes were cultured to blastocyst stage under optimized conditions in melatonin-supplemented media at either 10 M (MT 10) or 10 M (MT 10), or without supplementation (Culture + embryo transfer, or ET, positive control). Blastocysts were also developed in vivo (ET negative control).
Ambio
September 2025
Department of Sustainable Development, Environmental Science and Engineering (SEED), KTH Royal Institute of Technology, Stockholm, Sweden.
This study investigates how the seven core resilience principles are integrated into assessments of forest system resilience to natural or human-induced disturbances across engineering, ecological, and social-ecological resilience concepts. Following PRISMA guidelines, a literature search in the Web of Science database using the keywords "resilience", "forest" and "ecosystem services" yielded 1828 studies, of which 330 met the selection criteria. The most commonly used criterion was diversity, a sub-criterion of "diversity and redundancy", appearing in 50% of studies.
View Article and Find Full Text PDFObes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.